Denali Therapeutics (DNLI) Hisse Özeti
Bir biyofarmasötik şirketi olan Denali Therapeutics Inc. nörodejeneratif ve lizozomal depo hastalıklarını tedavi etmek için terapötikler keşfetmekte ve geliştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
DNLI Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Denali Therapeutics Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$21.09 |
| 52 Haftanın En Yüksek Seviyesi | US$27.30 |
| 52 Haftanın En Düşük Seviyesi | US$12.58 |
| Beta | 1.01 |
| 1 Aylık Değişim | -13.57% |
| 3 Aylık Değişim | -5.09% |
| 1 Yıllık Değişim | 48.63% |
| 3 Yıllık Değişim | -10.45% |
| 5 Yıllık Değişim | -60.08% |
| Halka arzdan bu yana değişim | -1.68% |
Son Haberler & Güncellemeler
Yeni Anlatı • Sep 04
Blood Brain Barrier Platform Risks Will Test This Rare Disease Pipeline Before Potential Upside
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?
Yeni Anlatı • Aug 21
Blood Brain Barrier Platform And Rare Disease Pipeline Will Shape Long Term Neurology Potential
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Aug 13
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Summary Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets. Valuation requires execution: AVLAYAH's commercial ramp and zafinofusp alfa's progress are critical, while Alzheimer’s programs offer significant long-term optionality. Read the full article on Seeking AlphaRecent updates
Yeni Anlatı • Sep 04
Blood Brain Barrier Platform Risks Will Test This Rare Disease Pipeline Before Potential Upside
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Yeni Anlatı • Aug 21
Blood Brain Barrier Platform And Rare Disease Pipeline Will Shape Long Term Neurology Potential
Catalysts About Denali Therapeutics Denali Therapeutics develops biologic medicines designed to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Aug 13
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Summary Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets. Valuation requires execution: AVLAYAH's commercial ramp and zafinofusp alfa's progress are critical, while Alzheimer’s programs offer significant long-term optionality. Read the full article on Seeking Alpha
Yeni Anlatı • Aug 07
Brain Delivery Platform And Rare Disease Portfolio Will Support Long-Term Upside Potential
Catalysts About Denali Therapeutics Denali Therapeutics focuses on biologic medicines engineered to cross the blood brain barrier for rare genetic and common neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • May 08
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Mar 20
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson’s Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact. Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Read the full article on Seeking AlphaSeeking Alpha • Jan 09
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Summary Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025. Financially, Denali has $1.28 billion in cash but may need additional funding in 2025, posing a risk of shareholder dilution. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 09
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Aug 20
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Summary Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company’s $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline. Despite its promising platform, DNLI still has a relatively high cash burn and regulatory hurdles before achieving drug approval. Due to Denali's high-risk, long-term biotech development, I deem DNLI a DCA "buy" for investors who understand the inherent risks. Read the full article on Seeking AlphaAnaliz Makalesi • Jul 26
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analiz Makalesi • May 23
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • May 13
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Summary Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II. Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024. Another promising program from the pipeline is the development of DNL-343, which is being advanced in the phase 2/3 HEALEY ALS Platform trial for treatment of patients with amyotrophic lateral sclerosis. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 17
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.71 Denali...Analiz Makalesi • Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Those holding Denali Therapeutics Inc. ( NASDAQ:DNLI ) shares would be relieved that the share price has rebounded 25...Seeking Alpha • Mar 07
Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Summary Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly. Recommends "buy" based on Denali's innovative TV technology, financial health, and potential in neurological disorders despite biotech risks. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 21
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analiz Makalesi • Jan 26
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right...Analiz Makalesi • Nov 20
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Hissedar Getirileri
| DNLI | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | -5.3% | -5.2% | -0.9% |
| 1Y | 48.6% | 37.6% | 14.2% |
Getiri vs. Endüstri: DNLI geçen yıl % 37.6 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: DNLI geçen yıl % 14.2 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| DNLI volatility | |
|---|---|
| DNLI Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
İstikrarlı Hisse Senedi Fiyatı: DNLI son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: DNLI 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2013 | 507 | Ryan Watts | www.denalitherapeutics.com |
Bir biyofarmasötik şirketi olan Denali Therapeutics Inc. nörodejeneratif ve lizozomal depo hastalıklarını tedavi etmek için terapötikler keşfetmekte ve geliştirmektedir. Şirket, periferik enflamatuar hastalıklar için Eclitasertib (SAR443122/DNL758) RIPK1 inhibitör programını; Parkinson hastalığı için BIIB122/DNL151 LRRK2 inhibitör programını geliştirmektedir; Frontotemporal demans-granulin için TAK-594/DNL593 programı; MPS IIIA (Sanfilippo Sendromu A) için DNL126 programı; ve MPS II (Hunter Sendromu) için bir enzim replasman tedavisi programı olan DNL310 Tividenofusp alfa. Enzim Taşıma Aracı (TV) programları arasında Pompe hastalığının tedavisi için DNL952; Parkinson ve Gaucher hastalıkları için DNL111; ve Hurler sendromu (MPS I) için DNL622 bulunmaktadır.
Denali Therapeutics Inc. Temel Bilgiler Özeti
| DNLI temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$3.37b |
| Kazançlar(TTM) | -US$511.45m |
| Gelir(TTM) | US$3.60m |
935.4x
P/S Oranı-6.6x
F/K OranıDNLI aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| DNLI gelir tablosu (TTM) | |
|---|---|
| Gelir | US$3.60m |
| Gelir Maliyeti | US$400.81m |
| Brüt Kâr | -US$397.21m |
| Diğer Giderler | US$114.24m |
| Kazançlar | -US$511.45m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -3.20 |
| Brüt Marj | -11,021.34% |
| Net Kâr Marjı | -14,191.20% |
| Borç/Özkaynak Oranı | 0% |
DNLI uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/13 11:19 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Denali Therapeutics Inc. 33 Bu analistlerden 19, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Charles Moore | Baird |